Education & Training

 

AGA Education, Practice and Research

Focused Clincial Updates 2006

To receive full CME credit, you are required to complete the evaluation form and self-test for each chapter you complete. Upon completion of the evaluation form and test, a certificate with your name and number of credits you have claimed will be generated. You must print your certificate using the print function in your browser.

The objectives listed below are to be used when evaluating the program. After completing this program, each participant should be able to:

  • Identify how state of the art and emerging research will impact management of digestive conditions.
  • Review diagnostic and treatment options for patients with several digestive diseases.

 

Motility Disorders: Top to Bottom

Select one answer for each question. You may change your answers as many times as you need to until you click the "Submit" button located at the bottom of the test.

1.Regarding long-term outcomes and causes of death in patients with achalasia:

The survival rate for patients with achalasia is less than the general population

The survival rate for patients with achalasia is similar to the general population

Pulmonary deaths are more common in patients with achalasia

B and C are correct

2. Predictive factors for clinical improvement with gastric elective stimulation in refractory gastroparesis:

Patients with nausea and vomiting responded poorer than patients with abdominal pain

Patients on narcotic analgesics had a favorable response

Patients with diabetic gastroparesis responded better than idiopathic gastroparesis

None of the above are correct

3. In patients with idiopathic gastroparesis:

Botulinum toxin injection into the pylorus is superior to placebo injection into the pylorus

Placebo injection into the pylorus resulted in better outcomes than Botox injection

There was no difference in improvement in patients receiving Botulinum toxin or placebo

None of the above are correct

4. Lubiprostone:

Results in improvement in constipation and abdominal pain compared to placebo in patients with constipation predominant irritable bowel syndrome

Adverse events are not dose-related

Is no different than placebo in improvement in constipation and abdominal pain in constipation predominant IBS

None of the above are correct